EMERGING-CTONG 1103: For Achieving High-Quality Evidence in a Randomized Phase II Trial

J Clin Oncol. 2020 Jan 20;38(3):285-286. doi: 10.1200/JCO.19.01976. Epub 2019 Dec 5.

Authors

Akiko Tateishi¹, Hiroto Ishiki¹, Emi Kubo¹, Eriko Satomi¹

Affiliation

¹ Akiko Tateishi, MD; Hiroto Ishiki, MD; Emi Kubo, MD; and Eriko Satomi, MD, National Cancer Center Hospital, Tokyo, Japan.

PMID: 31804860
DOI: 10.1200/JCO.19.01976

No abstract available

Publication types

Letter
Comment

MeSH terms

Carcinoma, Non-Small-Cell Lung*
Cisplatin
Deoxycytidine / analogs & derivatives
ErbB Receptors
Erlotinib Hydrochloride
Gemcitabine
Humans
Lung Neoplasms*
Neoadjuvant Therapy

Substances

Deoxycytidine
Erlotinib Hydrochloride
EGFR protein, human
ErbB Receptors
Cisplatin
Gemcitabine